Hydrogen Bromide → HCID 57882319, compound

HRID 1817370Notes

Reaction equation

HRID 1817370 reaction equation
[Cl:1][C:2]1[CH:3]=[C:4]([CH:23]=[CH:24][C:25]=1[F:26])[CH2:5][N:6]1[CH2:15][CH2:14][C:13]2[C:8](=[C:9]([O:20]C)[C:10](=[O:19])[N:11]([CH3:18])[C:12]=2[CH2:16][CH3:17])[C:7]1=[O:22].Br>C(O)(=O)C>[Cl:1][C:2]1[CH:3]=[C:4]([CH:23]=[CH:24][C:25]=1[F:26])[CH2:5][N:6]1[CH2:15][CH2:14][C:13]2[C:8](=[C:9]([OH:20])[C:10](=[O:19])[N:11]([CH3:18])[C:12]=2[CH2:16][CH3:17])[C:7]1=[O:22]

Participants

4

Reactant 2

HCID 260Hydrogen BromideHCID 69061871HCID 69061871, compound

Product 1

HCID 57882319HCID 57882319, compound

Reagents, catalysts & solvents 1

HCID 176Acetic AcidSolvent2×

Procedure

A solution of 2-(3-chloro-4-fluorobenzyl)-5-ethyl-8-methoxy-6-methyl-2,3,4,6-tetrahydro-2,6-naphthyridine-1,7-dione (55 mg, 0.15 mmol) and 33% HBr in acetic acid (5 mL) in acetic acid (10 mL) was stirred at room temperature overnight. The product mixture was concentrated under vacuum. The residue was subjected to preparative reverse phase HPLC purification. Collection and lyophilization of appropriate fractions provide the titled compound.

Workup

  1. concentrationThe product mixture was concentrated under vacuum
  2. customThe residue was subjected to preparative reverse phase HPLC purification
  3. customCollection and lyophilization of appropriate fractions

Sources & evidence

ORD record
ord-4bcbbc90fe7d401fa76bcac295c6e3b0
Source dataset
uspto-grants-2009_10
Patent number
US07598264B2

Reaction notes

Loading…